Aurinia Pharmaceuticals (IKAP) Stock Statistics & Valuation Metrics
Total Valuation
Aurinia Pharmaceuticals has a market cap or net worth of EUR 2.05B. The enterprise value is EUR 1.76B.
- Market Cap
- EUR 2.05B
- Enterprise Value
- EUR 1.76B
Share Statistics
Aurinia Pharmaceuticals has 133,998,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 133,998,660
- Owned by Insiders
- 12.70%
- Owned by Institutions
- 14.60%
Financial Efficiency
Aurinia Pharmaceuticals’s return on equity (ROE) is 0.49 and return on invested capital (ROIC) is 15.53%.
- Return on Equity (ROE)
- 0.49
- Return on Assets (ROA)
- 0.38
- Return on Invested Capital (ROIC)
- 15.53%
- Return on Capital Employed (ROCE)
- 0.16
- Revenue Per Employee
- 2.21M
- Profits Per Employee
- 2.24M
- Employee Count
- 128
- Asset Turnover
- 0.38
- Inventory Turnover
- 0.71
Valuation Ratios
The current PE Ratio of Aurinia Pharmaceuticals is 6.84. Aurinia Pharmaceuticals’s PEG ratio is 0.02.
- PE Ratio
- 6.84
- PS Ratio
- 6.75
- PB Ratio
- 3.29
- Price to FCF
- 12.37
- Price to Operating Cash Flow
- 12.31
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Aurinia Pharmaceuticals had revenue of 283.06M and earned 287.20M in profits. Earnings per share was 2.14.
- Revenue
- 283.06M
- Gross Profit
- 250.39M
- Operating Income
- 104.91M
- Pretax Income
- 114.16M
- Net Income
- 287.20M
- EBITDA
- 127.76M
- Earnings Per Share (EPS)
- 2.14
Cash Flow
In the last 12 months, operating cash flow was 175.67M and capital expenditures -132,585, giving a free cash flow of 175.54M billion.
- Operating Cash Flow
- 175.67M
- Free Cash Flow
- 175.54M
- Free Cash Flow per Share
- 1.32
Dividends & Yields
Aurinia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 8.06%
- Earnings Yield
- 14.49%
Stock Price Statistics
- Beta
- 0.18
- 52-Week Price Change
- 20.67%
- 50-Day Moving Average
- 14.28
- 200-Day Moving Average
- 13.43
- Relative Strength Index (RSI)
- 49.79
- Average Volume (3m)
- 100
Important Dates
Aurinia Pharmaceuticals upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Aurinia Pharmaceuticals as a current ratio of 5.25, with Debt / Equity ratio of 12.87%
- Current Ratio
- 5.25
- Quick Ratio
- 4.76
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.04
- Interest Coverage Ratio
- 24.23
Taxes
In the past 12 months, Aurinia Pharmaceuticals has paid -173.04M in taxes.
- Income Tax
- -173.04M
- Effective Tax Rate
- -1.52
Enterprise Valuation
Aurinia Pharmaceuticals EV to EBITDA ratio is 11.19, with an EV/FCF ratio of 12.48.
- EV to Sales
- 6.81
- EV to EBITDA
- 11.19
- EV to Free Cash Flow
- 12.48
- EV to Operating Cash Flow
- 12.47
Balance Sheet
Aurinia Pharmaceuticals has EUR 486.88M in cash and marketable securities with EUR 58.66M in debt, giving a net cash position of EUR 428.22M billion.
- Cash & Marketable Securities
- EUR 486.88M
- Total Debt
- EUR 58.66M
- Net Cash
- EUR 428.22M
- Net Cash Per Share
- EUR 3.20
- Tangible Book Value Per Share
- EUR 4.90
Margins
Gross margin is 90.73%, with operating margin of 48.60%, and net profit margin of 97.68%.
- Gross Margin
- 90.73%
- Operating Margin
- 48.60%
- Pretax Margin
- 51.94%
- Net Profit Margin
- 97.68%
- EBITDA Margin
- 60.86%
- EBIT Margin
- 54.84%
Analyst Forecast
The average price target for Aurinia Pharmaceuticals is EUR 16.99, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 16.99
- Price Target Upside
- 17.08% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- 15.36%
- EPS Growth Forecast
- 298.04%
Scores
- Smart Score
- 7
- AI Score
- ―
